medigraphic.com
ISSN 1561-2961 (Print)

2017, Number 1

<< Back Next >>

Rev Cuba Enf 2017; 33 (1)

Alzheimer's disease and environmental risk factors

Armenteros BFM

Language: Spanish
References: 39
Page: 159-172
PDF size: 112.62 Kb.


ABSTRACT

Introduction: Alzheimer disease is a neurodegenerative disease characterized for cognitive and conductual impairment with progressive beginning and course. There are many hypothesis about the disease that show from 20 percent of the persons with Alzheimer disease have a genetic injury and the difference of 80 percent of them are related with ambiental factors.
Objective: This review pretends show the ambiental risk factors associated to Alzheimer disease and the physiolocal and etiological mechanisms that cause it ethiological.
Methods: Actualized systematic approach it is based in data base CUMED and EBSCO. There are fifty cites an ten pertinents cites. Also an study and analysis selection was realized in both languages (English and Spanish). It was included research with different designs: prospective longitudinal metanalysis, aleatory clinical assays, and original investigations and revision articles for very importants authors.
Conclusions: There re diverse ambiental risk factors that contribute to Alzheimer disease. It is possible these ambientl risk factors coul begin in early etapes of the patients life and combine with other genetic factors.


REFERENCES

  1. Compdeclacreu J. Enfermedad de Parkinson y enfermedad de Alzheimer: factores de riesgo ambientales. Servicios de Neurología. Hospital Universitario de Bellvilge, España: Elsevier; 2011.

  2. Llibre Rodríguez JJ. Demencias y enfermedad de Alzheimer en la población cubana. La Habana, Cuba: Editorial Científico Técnica; 2008.

  3. Greicius MD. Menon-Default-mode activity during a passive sensory task: imcoupled from de activation but impacting activation. J cogn neurosci. 2004;169:1484-92.

  4. Wux Li R, Fleish AS, Reiman EM, Gilan N, Zang Y, Brelpitt C, et al. Altered default mode network connectivity en Alzheimer´s disease-a resting functional MRI an Bayesian network study. Hum. Brain Mapp. 2011;3211:1868-81.

  5. Peter R, Poulter R, Warner J, Beckell N, Burch L, Brelpitt C. Smoking, dementia and cognitive decline in the elderly, a systematic review. BMC geriatric. 2008;8:36.

  6. Wilson RS, Arnold SE, Schneider JA, Bennet, DA. Depressive Symptoms clinical AD, Chronic distress age related neuro-pathology and late life dementia. Pychosom med. 2007;69:47-53.

  7. Ho AJ, Rojo CA, Becker JJ, López OL, Kuller LH Hua X, et al. Obesity is linked with lowed brain volume in 700 AD and MCI patients. Neurobiol Aging. 2010;31:1326-39.

  8. Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta analysis. Am J Geriatric Psychiatry. 2008;16:343-54.

  9. Brust JC. Ethanol an cognition: indirect effects, neurotoxicity and neuroprotection: a review. Int J Environ Res Public Health 2010;7:1540-57.

  10. Posinetti GM. Novel role of red wine derived polyphenols in the prevention of Alzheimer disease dementia and brain pathology: experimental approvaches and clinical implication. Planta Med. 2012;785:1614-19.

  11. Chouliaros L, Sierksma. AS, Kenis G, Prickaerts J, Lemmeus MA, Brasn Jevie I, et al. Gene- envirment interaction research and transgenic mouse models of Alzheimer´s disease. Int J Alzheimer´s Dis. 2010;201:859-01.

  12. Barnes DE, Xaffe K. The proyectd, effect of risk factor reduction on Alzheimer´s disease prevalence. Lancet neurol. 2011;10:819-28.

  13. McGuines B, Tood S, Passmore P, Bullok R. Blood pressure lowering in patients without prior cerebrovascular disease of prevention of cognitive empairment and dementia. Cochrane Data base Syst Rev. 2009;4:CD 004054.

  14. Miyakawa T. Vascular pathology in Alzheimer´s disease. Psychogeriatric. 2010;10:39-44.

  15. Luchsinger JA. Deabetes, related conitions, and dementia. J neurol Sci. 2010;299:35-8.

  16. Kapogrannis D, Mattson MP. Disrupted energy metabolisan and neuronal circuit dysfunction in cognitive impairment and Alzheimer´s disease. Lancet Neurolg. 2011;10:187-98.

  17. Fernández - Gamba A, Seal MC, Morelli L, Castaño EM. Insulin degrading enzyme: Structure - functions relations hip and ist possible roles in health and disease. Curr Pharm Des. 2009;15:3644-5.

  18. Dukstein DL, Wolh J, Brautigam H, Stocktons D Jr, Gandy S, Hof PR. Role of vascular risk factor and vascular dysfunction in Alzheimer´s disease. Mt Sinai J Med. 2010;77:82-102.

  19. Brands AM, Bissels GJ, Kappelle LJ, de Han EH, de Valk HW, Algra A, et al. Cognitive functioning and brain MRI in patients with typed 1 and type 2 diabetes mellitus: A comparative study. Dement Geriart Cogn Desord. 2007;23:343.

  20. Salfrizzo V, Panza E, Frisordi V, Seripa D, Logroscino G, Imbimbo BP, et al. Diet and Alzheimer´s disease rick factor or prevention; the current evidence. Expert Rev neurother. 2011;11:677-708.

  21. Reijemer, von den Berg E, Ruiz C, Joap Kapelle L, Bresel GJ. Cognitive dysfunction in patients with type 2 diabetes. Diabetes metab. Res Rev. 2010;27:195-202.

  22. Thiehuis AM, Vincken KL, van den Berg E, Hendrikse JM an Shot SM, Moli WP, et al. Cerebral perfusion in relation to cognitive function an type 2 diabetes. Diabilologia. 2008;51:1321-6.

  23. Rolo A, Palmeira C. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress toxical. Appi Pharmacal. 2006;212:167-78.

  24. Corbett A, William G, Ballard C. Drug repositioning: an opportunity to develop novel treatment for Alzheimer´s disease. Pharmacenticals Basel. 2013;23(4):6-10.

  25. Lim HJ, Shim SB, Jee SW. Greentla catechin leads to global improvement aniong Alzheimer´s disease related phenotypes in NSE APPC 105. Nutri Biochen. 2013;247:1302-13.

  26. Serra JA, Marschoff ER, Domínguez R, Guareschi EM, Famulari AL, Pagano MA, et al. Oxidate stress in Alzheimer´s and vascular dementias: masking of the antioxidante profiles by a concomitant typeII diabetes Mellitus condition. Neurol Sci. 2004;218:17-4.

  27. Minge- Argiles JA, Sánchez Paya J, Muñoz-Ruiz C, Pampliega- Pérez A, Montoya-Gutiérrez A, Leyva Santana C. Biomarcadores en el LCR de pacientes con deterioro cognitivo leve: metaanálisis de su capacidad predictiva para el diagnóstico de la enfermedad de Alzheimer. Rev. Neurol. 2010;50:193-200.

  28. Verdelho A, Madureira S, Moleiro C, Ferro JM, Santos Co, Erkinjuntti T, et al. White matter charges and diabetes predict cognitive decline in the elderly. The Ladis study neurology rev. 2010;75:160-7.

  29. Nelson PT, Alafuzoff R, Bigio EH, Bouros C, Bruak H, Cairns NJ, et al. Correlation of Alheimer´s disease neuropathologic changes with cognitive status: review of the literature. J neuropathol Exp neurol. 2012;71:362-81.

  30. Montine TJ, Philps OH, Broch TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute in Againg Alzheimer´s Association guidilines ak for the neuropathologic assessment of Alzheimer´s disease. Alzheimer-Dement. 2012;8:1- 13.

  31. Guy Nieves JW, Stem Y, Luchsinger JA, Scarner SN. Food combustion and Alzheimer disease risk: a protective diet. Arch neurol. 2010;67:699-706.

  32. Domínguez RO, Marshoff ER, González SE, Reppeti MG, Serra JA. Typer 2 Diabetes and or its treatment leads to less cognitive impairment in Alzheimer´s disease patients. Diabetes Res Clin Proct. 2012;98:67-8.

  33. Simón AM, Frechilla D, del Rio J. Respectivas sobre la hipótesis e la cascada amiloide en la enfermedad de Alzheimer. Rev neurol. 2010;50:667-75.

  34. Lu FP, Lin Kuo HK. Diabetes and risk of multi-system aging phenotypes: a sistematic review and meta-analysis. Plos One. 2009;4:4144.

  35. Sanz C, Andrieu S, Sinclair A, Hanaire H, Villas B. Real for study group. Diabetes in associated with a slower rate of cognitive decline en Alzheimer´s disease. Neurology. 2009;73:1359-66.

  36. Cukierman-Yaffet, Gerstein HC, Williamson JD, Logar RM, Lobato M, Miller ME, et al. Relations hip between baseline glycemie control and cognitive function in individuale with type 2 and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in Diabetes ACCORD-MIND trial. Diabetes care. 2009;32:221-6.

  37. Domínguez RD, Marshoff ER, Guareschi EM, Repetto MG, Familiari AL, Pagano MA, Serra JA. Insulin, glucose and glycated hemoglobin in Alzheimer´s and without superimposed type II Diabetes Mellitus condition 5. Neurol Transm. 2008;115:77- 84.

  38. Llibre Rodríguez JJ. Síndrome demencial y factores de riesgo en adultos mayores e 60 años residentes en La Habana. Revista de Neurología. 2014;32:22-6.

  39. Irie F, Fitzpatrik AL, López OL, Kuller LH, Peila R, Newman AB, et al. Enhanced risk for AD in persons with type 2 diabetes and APDE epsilon 4 the cardiovascular Health Study cognition. Study Arch neurology. 2008;65:89-93.




2020     |     www.medigraphic.com